Collaborative research aiming to develop innovative treatments over a 10-year period
T-CiRA is a joint research program by the Center for iPS Cell Research and Application (CiRA), Kyoto University and Takeda Pharmaceutical Company Limited. Over a 10-year period and under the direction of CiRA, this joint program will conduct research to develop clinical applications of iPS cells. We aim to develop innovative drugs and cell treatments in such areas as heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases in order to fulfill the needs of patients promptly.
Professor Shinya Yamanaka
Director of Center for iPS Cell Research and Application (CiRA), Kyoto University
"This 10-year joint program with Takeda, Japan's largest pharmaceutical company, will become a powerful engine to realize medical applications using iPS cells," said Yamanaka. "We sincerely thank Takeda's commitment to iPS cell research. This partnership will contribute to the development of new therapies to cure not only major diseases but also rare ones."
Representative Director, President & CEO, Takeda
"I am excited that we will be able to collaborate with CiRA, the world's leading institute dedicated to pioneering iPS cell research," said Christophe Weber, President, and Chief Executive Officer of Takeda. "Through this partnership, our company will provide significant assistance over a long period to CiRA's research into iPS cell technology applications, which is a vital part of Japan Revitalization Strategy. It is our hope to deliver innovative treatments that meet patient needs as soon as possible through this collaboration between Takeda and CiRA."
T-CiRA (Takeda-CiRA) Joint Program Framework
Leader: Professor Shinya Yamanaka (Director of CiRA)｜Goal: Develop clinical application of induced pluripotent stem (iPS) cells｜Areas: Heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases, etc.
- To provide collaborative funding of 20 billion yen over a 10-year period
- To provide more than 12 billion yen worth of research support
- To provide R&D know-how
- To provide research facilities at Shonan Research Center
- To provide platform for drug development
- To provide access to compound libraries
- To provide researchers
- To direct the research program
- To provide iPS cell technologies
- To provide drug development targets and assay systems
- To provide principle investigators, researchers and postdoctoral fellows
Shonan Health Innovation Park
A global research center, created by merging the Osaka and Tsukuba Research Centers, helps accelerate innovations in drug development. Here, approximately 1,200 researchers conduct non-clinical research from the early stages of the R&D process such as drug targeting and compound candidate selection to placing drugs on the market.